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Abstract
Background—In March 2009, the U.S. Food and Drug Administration licensed an inactivated, 
Vero cell culture-derived Japanese encephalitis vaccine (JE-VC [Ixiaro]) for use in adults. The 
vaccine was licensed based on clinical trial safety data in 3558 JE-VC recipients. It is essential to 
monitor post-licensure surveillance data to evaluate the safety of JE-VC because rare adverse 
events may not be detected until the vaccine is administered to a larger population.
Methods—We reviewed adverse events reported to the U.S. Vaccine Adverse Event Reporting 
System (VAERS) for adults (≥17 years) who received JE-VC from May 2009 through April 2012. 
Adverse event reporting rates were calculated using 275,848 JE-VC doses distributed.
Results—Over the 3 year period, 42 adverse events following vaccination with JE-VC were 
reported to VAERS for an overall reporting rate of 15.2 adverse events per 100,000 doses 
distributed. Of the 42 total reports, 5 (12%) were classified as serious for a reporting rate of 1.8 per 
100,000 doses distributed; there were no deaths. Hypersensitivity reactions (N = 12) were the most 
commonly reported type of adverse event, with a rate of 4.4 per 100,000 doses distributed; no 
cases of anaphylaxis were reported. Three adverse events of the central nervous system were 
reported (one case of encephalitis and two seizures) for a rate of 1.1 per 100,000; all occurred after 
receipt of JE-VC with other vaccines.
Conclusions—These post-marketing surveillance data suggest a good safety profile for JE-VC 
consistent with findings from pre-licensure clinical trials. Post-licensure safety data should 
continue to be monitored for any evidence of rare serious or neurologic adverse events.
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1. Introduction
Japanese encephalitis (JE) virus, a mosquito-borne flavivirus, is the leading cause of 
vaccine-preventable encephalitis in Asia [1]. JE is a serious disease with a case-fatality rate 
of 20–30% and sequelae in 30–50% of survivors. The risk of JE for most travelers to Asia is 
very low but varies based on season, destination, duration, and activities [2]. The U.S. 
Advisory Committee on Immunization Practices (ACIP) recommends JE vaccine for 
travelers who plan to spend ≥1 month in endemic areas during the JE virus transmission 
season; JE vaccine should be considered for short-term (<1 month) travelers with higher risk 
itineraries [3].
In March 2009, the U.S. Food and Drug Administration (FDA) licensed an inactivated, Vero 
cell culture-derived Japanese encephalitis vaccine (JE-VC [Ixiaro]) for use in adults aged 
≥17 years [4]. JE-VC is administered in a 2-dose primary series at 0 and 28 days. If the 
primary series was administered >1 year previously, a booster dose may be given before 
potential JE virus exposure [5]. Prior to JE-VC becoming available, an inactivated mouse 
brain-derived JE vaccine (JE-MB [JE-VAX]) was the only JE vaccine licensed in the United 
States [3]. JE-MB was associated with rare but serious allergic and neurologic adverse 
events [6]. Allergic hypersensitivity reactions reported included generalized urticaria and 
angioedema of the face, oropharynx, and extremities; neurologic events included acute 
disseminated encephalomyelitis temporally-associated with vaccination [2]. In 2006, the 
manufacturer ceased production of JE-MB and all supplies expired by May 2011 [7].
JE-VC was licensed based on clinical trial safety data in 3558 JE-VC recipients. No 
important safety concerns were identified [8–10]. However, it is essential to monitor post-
licensure surveillance data to evaluate the safety of JE-VC in a larger population [3]. We 
analyzed adverse events reported to the U.S. Vaccine Adverse Event Reporting System 
(VAERS) in adults who received JE-VC during the first 3 years post-licensure. Based on the 
adverse event profile of the previously-available JE-MB, we focused on serious, 
hypersensitivity, and neurologic adverse events.
2. Methods
2.1. VAERS
VAERS is a national passive surveillance system for monitoring adverse events following 
immunization [11]. VAERS is co-administered by the U.S. Centers for Disease Control and 
Prevention (CDC) and FDA. Vaccine manufacturers, healthcare providers, and vaccine 
recipients submit reports online, by fax, or by mail, using a standardized form that includes 
data on patient demographics, vaccination, and adverse events. VAERS administrators assign 
Medical Dictionary for Regulatory Activities (MedDRA) codes to the reported adverse 
events. For individual VAERS reports, the causal relationship between vaccination and 
reported events cannot usually be determined.
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2.2. Case definitions and classification
We reviewed reports of adverse events received by VAERS as of May 1, 2013 following 
administration of JE-VC to adults (≥17 years) from May 1, 2009 through April 30, 2012, 
either in the United States or to U.S. military personnel stationed abroad. We defined onset 
interval as the number of days from vaccination (Day 0) until the first reported symptom. 
Reports were excluded if the onset interval was >60 days (N = 2, including one report of 
anaphylaxis 67 days after receipt of JE-VC and one report of acute myelogenous leukemia 
with onset 110 days after receipt of JE-VC), or if the only event that occurred was a local 
reaction in the arm contralateral to where JE-VC was administered (N = 5). Reports were 
also excluded if they described errors in vaccine administration but no adverse event (i.e., 
administration of JE-VC during pregnancy [N = 1] and administration of expired vaccine [N 
= 1]). Additionally, one report was excluded because a retrospective record review 
confirmed that the report was based on a disease coding error and there was no adverse 
event; another report was excluded because it listed only the coding term “convulsion” but 
contained no data on patient demographics, date of vaccine receipt, or date of adverse event 
onset.
A serious adverse event was defined according to the FDA regulatory definition (21 CFR 
600.80) as life-threatening or resulting in death, inpatient hospitalization or prolongation of 
existing hospitalization, persistent or significant disability, or a congenital anomaly/birth 
defect [12]. Adverse events were classified as anaphylaxis if they met level 1 or level 2 of 
diagnostic certainty using the Brighton Collaboration case definition, and occurred within 2 
h of vaccination [13]. An adverse event report was classified as a hypersensitivity reaction if 
any of the major or minor dermatologic/mucosal or respiratory criteria of the Brighton 
Collaboration case definition for anaphylaxis were present and occurred within 14 days of 
vaccination [6,13]. Hypersensitivity reactions were classified as “immediate” if onset 
interval was <2 h and “delayed” if onset interval was 2 h to 14 days after vaccination. 
Adverse events classified as central neurologic events included aseptic meningitis, 
encephalitis, myelitis, acute disseminated encephalomyelitis (ADEM), Guillain-Barré 
syndrome (GBS), or generalized seizure that met level 1 or level 2 of diagnostic certainty of 
the Brighton Collaboration case definitions for those conditions [14–17]. Adverse events 
were classified as peripheral neurologic adverse events if they were confined to the 
peripheral nervous system (e.g., paresthesia and peripheral neuritis).
2.3. Data collection and analysis
We reviewed VAERS reports for patient age, sex, concurrent vaccine administration, onset 
interval, MedDRA coding terms, symptom text, and outcome. Medical records, which are 
routinely obtained for serious adverse events, were reviewed. Starting in August 2010, we 
also contacted the vaccine recipient or healthcare provider to obtain additional clinical data 
on reports of serious, hypersensitivity, or neurologic reactions. For reports which included 
multiple coding terms, the key event was determined. Because VAERS is a routine 
surveillance program conducted as a public health function, it is not subject to Institutional 
Review Board review and informed consent requirements.
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The analysis was conducted by unique case report. The incidence of all, serious, 
hypersensitivity, and neurologic adverse events reported following vaccination with JE-VC 
were calculated per 100,000 doses distributed during the 3 year period. Based on data 
obtained from Valneva Austria GmbH (formerly Intercell Biomedical) and Novartis 
Vaccines, 275,848 JE-VC doses were distributed to the U.S. private market and military 
from May 2009 through April 2012. No information was available regarding the numbers of 
vaccine doses administered or the age and sex of vaccine recipients.
3. Results
3.1. Adverse event reports following receipt of JE-VC
During the 3 year period, 42 adverse events following receipt of JE-VC were reported to 
VAERS and met the inclusion criteria for an overall reporting rate of 15.2 adverse events per 
100,000 doses distributed (Table 1). Twenty-two (52%) of the reported events occurred in 
males and the median age was 31 years (range 19–59 years) (Table 2). Adverse events 
occurred a median of 1 day after vaccination (range 0–39 days); 38 (90%) occurred within 2 
weeks of vaccination. Twenty-seven (64%) events occurred after the first dose of JE-VC and 
10 (24%) followed a second dose.
JE-VC was listed as the only vaccine administered in 17 (40%) of the 42 reports. Among the 
other 25 reports, a median of two vaccines (range 1–5) was administered at the same time as 
JE-VC. The most common concurrently administered vaccines were typhoid (N = 8), 
hepatitis A (N = 7), hepatitis B (N = 6), rabies (N = 6), anthrax (N = 5), tetanus/diphtheria/
acellular pertussis (Tdap) (N = 4), smallpox (N = 3), and influenza (N = 2). There were no 
substantial differences in the median age, sex, or onset intervals between events that 
occurred following JE vaccine administered alone or with other vaccines (Table 3).
3.2. Classification of adverse events
Of the 42 adverse events reported, 5 (12%) were classified as serious and 37 (88%) as non-
serious; 12 (29%) reports were classified as hypersensitivity reactions and three (7%) as 
central neurologic events. The 22 reports that did not meet the case definition for serious, 
neurologic, or hypersensitivity adverse events, included fever (N = 10), musculoskeletal pain 
(N = 3), local reactions (N = 3), nonspecific somatosensory complaints (N = 3), rashes (N = 
2), and syncope (N = 1).
3.2.1. Serious adverse events—Five (12%) adverse events were classified as serious 
for a reporting rate of 1.8 per 100,000 doses distributed (Table 1). These occurred in males 
with a median age of 40 years (range 20–56) (Table 2). Three serious events occurred 
following a first dose, one following a second dose, and one report did not include the dose 
number. Four of the patients with serious adverse events were hospitalized and one was 
observed for a “life-threatening illness” but not hospitalized. There were no deaths.
JE-VC was the only vaccine administered for two of the reports (Table 4). One was a 
delayed hypersensitivity event and the other was a patient who developed abdominal pain at 
5 days post-vaccination and had an appendectomy for appendicitis. The other three serious 
adverse events were reported following administration of JE-VC with other vaccines. One 
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was classified as an immediate hypersensitivity reaction and one as a neurologic event 
(encephalomyelitis). The remaining serious report was a patient who developed chest pain at 
11 days after receiving JE-VC, smallpox, anthrax, and typhoid vaccines and was diagnosed 
with myopericarditis. He was hospitalized for 3 days and discharged after clinical 
improvement.
3.2.2. Hypersensitivity reactions—Overall, 12 (29%) reports were classified as 
hypersensitivity reactions, for a rate of 4.4 per 100,000 doses distributed (Table 1). Six 
(50%) occurred in males and the median age of patients was 33 years (range 19–59). Seven 
(58%) occurred following a first dose of JE-VC and five (42%) following a second dose. 
Seven (58%) occurred after vaccination with JE-VC alone and five (42%) after concomitant 
administration of JE-VC with other vaccines (Table 4). Ten (83%) events had onset ≤1 day 
after vaccination, one at 2 days after vaccination, and one at 10 days after vaccination. Four 
(33%) were immediate (<2 h after vaccination) and eight (67%) were delayed 
hypersensitivity. Two hypersensitivity reactions (one immediate and one delayed) were 
classified as serious adverse events. No reports met the case definition for anaphylaxis.
Of the four immediate hypersensitivity reactions, two occurred in males and the median age 
of patients was 26 years (ranged 19–45). Onset ranged from 5 to 90 min after vaccination 
(median 13 min). Two occurred after administration of JE-VC alone, one after a first dose, 
and one after a second dose. Two occurred after administration of JE-VC with other 
vaccines, both following a first dose of JE-VC. Three patients had dyspnea and a sensation 
of throat closure and one had generalized urticaria. None had cardiovascular symptoms and 
none were treated with epinephrine; however, all received diphenhydramine.
The eight delayed hypersensitivity events occurred equally among males and females with a 
median age of 45 years (range 21–59 years). The onset interval ranged from 2 h to 10 days 
(median 1 day); 7 (88%) occurred within 3 days following vaccination. One report 
documented generalized urticaria with onset 10 days after the subject received JE-VC, 
smallpox, and anthrax vaccines; however, he also completed a 10-day course of oral 
amoxicillin 1 day prior to onset. Four events (50%) followed a first dose of JE-VC and five 
events (63%) occurred after vaccination with JE-VC alone. Overall, clinical findings 
included generalized urticaria (N = 4), generalized pruritic maculopapular rash (N = 1), 
localized pruritic rash (N = 1), dyspnea and cough (N = 1), and sensation of tongue swelling 
and numbness (N = 1). The patient who had sensation of tongue swelling and numbness 
after receiving JE-VC, hepatitis B, rabies, and typhoid vaccines, reported experiencing a 
similar event when she received JE-MB approximately 9 years earlier.
3.2.3. Neurologic events—One reported adverse event met the case definition for 
encephalomyelitis and two for seizures. There were no reports of aseptic meningitis, GBS, 
or ADEM following immunization with JE-VC vaccine. The three central neurologic 
adverse event reports constitute a reporting rate of 1.1 per 100,000 doses distributed.
The case of encephalomyelitis occurred in a 20-year-old male soldier who had onset of 
headache, altered mental status, photophobia, upper motor neuron signs, and pleocytosis at 
39 days after receiving his first dose of JE-VC, which was administered concomitantly with 
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oral typhoid, smallpox, and hepatitis A/hepatitis B vaccines. Five days before his onset of 
symptoms he received another dose of smallpox vaccine because of failure to develop an 
appropriate immune response to the previous dose. He was hospitalized for 2 days and 
recovered with no complications.
One seizure report described loss of consciousness and abnormal limb movements in a 35-
year-old female with underlying neuropsychiatric conditions. The event was witnessed by 
medical staff and occurred immediately after the patient received JE-VC, Tdap, hepatitis A, 
and rabies vaccines. The other seizure report described loss of consciousness, jerking limb 
movements, and vomiting in a 30-year-old female at 8 h after receiving JE-VC and rabies 
vaccines; the event was witnessed by friends at home. This patient had also ingested a 
homeopathic preparation and cannabis on the same day. She was medically evaluated as an 
outpatient in the subsequent week.
There were also three reports of peripheral neurologic adverse events. These included one 
report of upper limb neuritis in the arm where JE-VC was administered (with hepatitis A/
hepatitis B vaccine administered in the contralateral arm), one report of paresthesia in the 
limb where JE-VC was administered with meningococcal vaccine, and one report of 
generalized paresthesia following administration of JE-VC with hepatitis A and varicella 
vaccines.
4. Discussion
A total of 42 adverse events following receipt of JE-VC vaccine were reported to VAERS 
during the first 3 years post-licensure when over 275,000 doses were distributed. The most 
frequently reported events were hypersensitivity reactions and fever. Most events were non-
serious, no unexpectedly high reporting rates for specific events were identified, and no 
deaths were reported. Although the possibility of rare serious adverse events associated with 
this vaccine cannot be excluded, these post-marketing data support the safety profile of JE-
VC from pre-licensure clinical trials.
The overall rate of 15.2 adverse events per 100,000 doses distributed is similar to the rate 
reported to VAERS for JE-MB from 1993–1999 (15.0 per 100,000 doses distributed) and 
lower than that reported for JE-MB from 1999–2009 (23.7 per 100,000 doses) [6,18]. The 
reporting rate for serious adverse events following JE-VC was equivalent to the rate detected 
following JE-MB (1.8 per 100,000 doses), and may reflect concomitant administration of 
JE-VC with other reactogenic vaccines [6]. From 2009 to 2012, three (60%) of the five 
reported serious adverse events occurred following receipt of JE-VC with other vaccines. 
These included one report each of myopericarditis and encephalomyelitis in patients who 
had also received smallpox vaccine. Myocarditis is a well-described complication following 
smallpox vaccination; encephalitis has also been reported [19].
Hypersensitivity reactions were reported in 12 recipients; most included primarily 
dermatological symptoms and none met the case definition for anaphylaxis. Eleven of the 
reactions occurred within 2 days after vaccination. Other etiologies for such reactions cannot 
be ruled out, but the temporal association may support a causal association with JE-VC 
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vaccination, especially for the seven hypersensitivity reactions that occurred among persons 
vaccinated with JE-VC alone. Gelatin, used as a vaccine stabilizer in JE-MB and considered 
a possible cause of the allergic hypersensitivity reactions occurring following JE-MB, is not 
present in JE-VC, leading to the assumption that JE-VC might be associated with fewer 
hypersensitivity events [20]. In this analysis, the reporting rate for hypersensitivity reactions 
following JE-VC was 4.4 per 100,000 doses distributed compared with 6.3–8.4 per 100,000 
doses following JE-MB [6,18].
We identified one report of hypersensitivity following JE-VC in a patient who experienced 
similar symptoms following previous vaccination with JE-MB. A recent case report 
describing a patient who had a hypersensitivity reaction following a dose of JE-MB and 
again following a dose of JE-VC administered 3 years later suggested that a common factor 
in both vaccines may be responsible, possibly JE virus antigen [21]. However, any 
conclusions are limited by the small numbers and inability to determine causality in these 
reports.
Three central neurologic events following JE-VC were reported, for a rate of 1.1 per 
100,000, compared with 0.3 per 100, 000 doses distributed following JE-MB. However, 
these events occurred after JE-VC administered on the same day as other vaccines. 
Furthermore, the encephalomyelitis case occurred 39 days after JE-VC vaccination and only 
5 days after a repeat smallpox vaccination. Similarly, the two reports of seizures occurred in 
patients with possible alternative etiologies. For JE-MB, concerns were raised regarding the 
potential for neurologic adverse effects because of murine neural proteins introduced 
through mouse brain passage. The production and formulation of JE-VC does not pose the 
same concerns [3,8–10].
Pre-licensure clinical trials of JE-VC did not identify any important safety concerns or 
specific events that required post-surveillance monitoring [8–10,22]. The vaccine 
manufacturer evaluated post-marketing surveillance data from the first 12 months (April 
2009–March 2010) following licensure in Europe, Australia, and the United States [22]. 
That analysis showed a lower rate of all adverse events (10.1 per 100,000 doses distributed) 
than the VAERS data from 2009 to 2012 reported here. This variation in findings may be 
due to differences in the study populations, surveillance systems, reporting criteria, or case 
classification. In addition, the proportion of distributed doses that are administered or 
awareness about the vaccine and adverse events may have changed over time. Importantly, 
the current and previous analyses showed similar reporting rates per 100,000 doses 
distributed for both serious adverse events (1.8 and 1.6) and hypersensitivity reactions (4.4 
and 4.5 per 100,000).
This report is subject to several limitations. VAERS is a passive surveillance system 
dependent on clinician or patient recognition and reporting of events [11]. The temporal 
association of an adverse event with vaccination does not prove a causal relationship. The 
lack of data on the number of doses administered versus distributed precludes the calculation 
of the true incidence of adverse events. From 1993–2009, >2 million doses of JE-MB were 
distributed, compared to <300,000 doses of JE-VC distributed from 2009 to 2012; this 
difference in numbers of doses distributed and any differences in reporting to VAERS over 
Rabe et al. Page 7
Vaccine. Author manuscript; available in PMC 2018 January 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the analysis periods limits the ability to accurately compare rates of adverse events for JE-
VC and JE-MB. The relatively low number of JE-VC doses distributed over the reporting 
period may have precluded detection of rare adverse events.
5. Conclusions
The risk of travel-associated JE is low. However, there is no effective treatment, case fatality 
is high, and sequelae among survivors is substantial. Therefore, travelers with itineraries that 
place them at higher risk of infection should receive JE vaccine. These post-marketing 
surveillance data from the first 3 years post-licensure support the good safety profile 
documented in pre-licensure clinical trials. The apparent higher rate of central neurologic 
adverse events following JE-VC compared to JE-MB is likely artifactual but requires 
continued monitoring. In May 2013, FDA licensed JE-VC for use in children aged 2 months 
through 16 years and use in this age group was subsequently approved by the ACIP. Post-
marketing surveillance safety data should continue to be monitored for any evidence of rare 
serious or neurologic adverse events in adults or children. Providers should report clinically 
significant adverse events following JE-VC to VAERS (www.vaers.hhs.gov).
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Table 3
Adverse events reported to VAERS following receipt of inactivated Vero cell culture-derived Japanese 
encephalitis vaccine (JE-VC) when administered alone or with other vaccines, United States, May 2009–April 
2012.a
JE-VC administered alone (N = 17) JE-VC administered with other vaccines (N = 25)
No. (%) No. (%)
Male sex 7 (41) 10 (40)
Serious adverse events 2 (12) 3 (11)
JE-VC vaccine dose
 First 8 (47) 20 (80)
 Second 6 (35) 4 (16)
 >2 doses 2 (12) 0 (0)
 Unknown 1 (6) 1 (4)
Event classification
 Hypersensitivity 7 (41) 5 (19)
 Neurologic 0 (0) 6 (11)
 Other event 10 (59) 14 (70)
aVAERS, Vaccine Adverse Event Reporting System.
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